Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors.

ABSTRACT:

Background

HIV-1 can develop resistance to antiretroviral drugs, mainly through mutations within the target regions of the drugs. In HIV-1 protease, a majority of resistance-associated mutations that develop in response to therapy with protease inhibitors are found in the protease's active site that serves also as a binding pocket for the protease inhibitors, thus directly impacting the protease-inhibitor interactions. Some resistance-associated mutations, however, are found in more distant regions, and the exact mechanisms how these mutations affect protease-inhibitor interactions are unclear. Furthermore, some of these mutations, e.g. N88S and L76V, do not only induce resistance to the currently administered drugs, but contrarily induce sensitivity towards other drugs. In this st

SUBMITTER: Bastys T 

PROVIDER: S-EPMC7236880 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature